Special Issue "The Global Need for New Antimicrobial and Antibiofilm Agents"
Deadline for manuscript submissions: 31 December 2021.
Interests: antimicrobial activity; antibiofilm activity; antimicrobial peptides; antivirulence drugs; antibiotic resistance
Interests: molecular microbiology; antimicrobials; antibiofilm activity; antimicrobial peptides; antivirulence drugs; antibiotic resistance
Modern medicine and even the structure of society are established on the ability to control infectious diseases. Antibiotics and vaccines represent the two fundamental pillars on which the ability to manage and fight pathogens is based. However, one of the two pillars falters due to antimicrobial resistance (AMR). Bacterial resistance may develop at cellular level (mutations or horizontal gene transfer) and sessile community, based on adaptive resistance and tolerance involving shift from free-living cells to a biofilm community. It is estimated that, in clinical settings, at least 60% of infections are due to biofilms, which are often the cause of polymicrobial and chronic infections. Moreover, in many cases, antimicrobials used in agriculture and animal breeding are equal to the ones used in clinical settings, increasing the risk of the rise and spread of resistant bacteria, including common pathogens for both animals and humans. Reducing antibiotic usage in farms and replacing it with new molecules could be a short-term approach to facing AMR.
New antimicrobials that are able to hit resistant pathogens and biofilm are strongly needed. It is time for action in order to address antibiotic-resistant strains, especially carbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter baumannii (CRAB) and Pseudomonas aeruginosa (CRPA), which are resistant to last-resort antibiotics.
This Special Issue is aimed at researchers who focus their scientific interest on drug discovery strategies to develop new molecules with antimicrobial action and antibiofilm. Potential topics may include but are not limited to antimicrobial peptides of various organisms, natural substances, nanoparticles of microbial origin, and small synthetic organic molecules. Topics such as strategies aimed at improving the efficiency of conventional antibiotics through nano/micro-release and micro-release systems with functionalized polymers are also welcome.
Prof. Dr. Domenico Schillaci
Dr. Valentina Catania
Dr. Maria Vitale
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antimicrobial agents
- antibiofilm agents
- anti-virulence agents
- antimicrobial peptides
- natural substance
- synthetic small organic molecules
- improvement of conventional antibiotics